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Abstract: Oxytocin is a natural hormone with uterine stimulant properties that plays a 
prominent role in obstetric practice. Clinical guidelines for oxytocin use intrapartum 
emphasise that injudicious use has serious potential for adverse outcomes for mother 
and baby. Oxytocin is readily available in South Asia and widely used in ways that 
flout these guidelines. Yet recommendations for active management of third stage 
of labour (AMTSL) include the administration of oxytocin to prevent post-partum 
haemorrhage (PPH). Troublingly, these proposals seem to ignore oxytocin’s already 
extensive life independent of policy interventions. Taking oxytocin as an example, the 
paper argues that policy-makers urgently need to engage with the everyday realities 
of drug availability and use in South Asia.
I
Introduction
Oxytocin is a natural hormone with uterine stimulant properties that plays a prominent 
role in obstetric practice. It was first synthesised by Du Vigneaud in 1953 [Mousa and 
Alfirevic, 2007]. In the late 1960s O’Driscoll advocated oxytocin use intrapartum 
as a component of active management of labour (AML i.e. first and second stage of 
labour, before the baby is born), a package aimed at limiting the length of labour in 
nulliparous women [O’Driscoll and Meagher, 1980]. Later, oxytocin was found to be 
effective in preventing and controlling post-partum haemorrhage (PPH) in the third 
34Intrapartum Oxytocin (Mis)use in South Asia / Brhlikova, Jeffery, Bhatia, Khurana
stage of labour [Prendiville, Elbourne, and McDonald, 2000].  PPH is regarded as a key 
cause of maternal mortality throughout the Global South—estimates for India suggest 
that between 31 per cent and 38 per cent of maternal deaths are due to haemorrhage 
[Registrar-General India, 2006: 17,15]. Proposals for the active management of the 
third stage of labour (AMTSL) include administration by local-level government health 
workers, such as nurse-midwives, of either oxytocin (by intramuscular injection) or 
misoprostol (administered by pill). 
Yet oxytocin is widely available and used in the formal health care system in South Asia, 
even in apparently remote rural areas. Moreover, the clinical guidelines for intrapartum 
oxytocin use are often flouted, whether in urban nursing homes and hospitals or in rural 
home births. Injudicious intrapartum use of oxytocin has serious potential for adverse 
outcomes, including uterine rupture and foetal asphyxia. This understanding motivated 
us to include oxytocin in the Tracing Pharmaceuticals project and our concerns have 
subsequently been enhanced by the proposals for AMTSL that would extend its 
availability even further. 
II
Clinical Guidelines for the Use of Oxytocin
We begin by outlining the clinical evidence and guidelines related to oxytocin use 
to augment labour (in first and second stages) and to prevent and treat PPH in the 
third stage of labour. Oxytocin is also used to “abort the fetus in cases of incomplete 
abortion or miscarriage” [www.drugs.com accessed 25/09/07], but we shall not discuss 
this use here.
Oxytocin in the intrapartum period
Augmentation of labour increases the frequency, duration and strength of contractions. 
In the first stage, the intention is to cause the cervix to dilate and in the second stage, 
to cause the head to descend. The clinical guidelines formulated by O’Driscoll and 
Meagher for oxytocin use in AML were based on their 14 years of practice in the National 
Maternity Hospital in Dublin [O’Driscoll and Meagher, 1980]. Apart from oxytocin, the 
AML package includes a strict definition of labour, amniotomy and continuous support 
during labour in order to avoid the potential risks associated with oxytocin use. Table 
1 summarises the conditions under which they and others recommend that oxytocin be 
used intrapartum.
35 Journal of Health Studies / II / 2009
Table 1: Intrapartum Oxytocin Use: Clinical Guidelines*
Exclusion of at-risk women Contra-indications include: hypertonic uterine 
contractions, foetal distress, any condition where 
spontaneous labour or vaginal delivery are inadvisable, 
prolonged administration in oxytocin-resistant 
uterine inertia, severe pre-eclamptic toxaemia, severe 
cardiovascular disease, impaired placental function 
which might lead to hypoxia.
Parity Recommended only for nulliparous women. In 
multiparas, inefficient uterine action is rare and slow 
progress of labour is more likely to be associated 
with other causes (e.g. foetal malpresentation or 
malformation). Multiparas are prone to uterine rupture 
and oxytocin stimulation increases the risk of rupture, 
so oxytocin should be used in multiparas only in 
exceptional cases determined by the obstetrician.
Examination prior to oxytocin administration A strict definition of labour to admit only women in 
labour. Oxytocin use is conditional on there being a 
single foetus in vertex presentation.
Mode of administration Artificial rupture of membranes is the first intervention 
offered in the case of slow progress of labour (less 
than 1cm dilatation per hour): this is often sufficient to 
augment labour. Moreover, oxytocin is often ineffective 
with intact membranes and can increase the risk of 
infusion of amniotic fluid into maternal circulation. 
Oxytocin may cause hyperstimulation of the uterine 
muscles and the effective dose varies across women. 
To ensure optimal contractions, oxytocin should be 
administered cautiously by intravenous infusion and 
stopped immediately if hyperstimulation or foetal 
distress occurs. 
Monitoring the woman & foetus during oxytocin 
administration    
All labouring women should be assigned a personal 
nurse who is present from admission until the baby is 
born. After amniotomy, vaginal examinations should be 
performed hourly. To detect uterine hyperstimulation or 
foetal distress, the progress of labour and interventions 
should be detailed on a partograph, recording 
contractions, mother’s blood pressure & foetal heart 
rate (the latter by direct auscultation for one minute 
every 15 minutes during the first stage and after each 
contraction during the second stage). 
Setting/availability of emergency facilities: AML recommended only for institutional deliveries in 
facilities with adequate equipment to deal with obstetric 
emergencies (e.g. Caesarean section or resuscitation of 
the infant).
* See O’Driscoll and Meagher [1980] and British National Formulary 
http://www.bnf.org/bnf/bnf/current/4499.htm?q= per cent22oxytocin per cent22# (accessed 4 March 2009)
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Since AML was first proposed in the 1960s, the practice with or without modifications 
“has been widely adopted across the world” [WHO, 1996]. The recent literature 
suggests that oxytocin is used intrapartum in the majority of deliveries in the US “with 
augmentation being more the rule than the exception” [Freeman and Nageotte, 2007: 
445]. A review of studies on the use of oxytocin and misoprostol in seven low-income 
countries showed that up to 50 per cent of deliveries in public hospitals were induced 
or augmented (up to 20 per cent in Ethiopia and Tanzania, and 40-50 per cent in the 
other five countries) [Lovold, Stanton, and Armbruster, 2008]. Such high percentages 
of induced and augmented labours are worrying in the context of developing countries 
where “current evidence-based guidelines are rare, care is less regulated, and staffing 
and monitoring capabilities are limited … [o]xytocin is often administered without the 
aid of a precise dose/time regulatory infusion pump, external fetal monitor […] or one-
on-one care” [Lovold et al., 2008: 277]. 
The concerns over the frequent use of oxytocin intrapartum, however, extend to 
developed countries. Oxytocin as a drug associated with ‘a heightened risk of harm’ 
and one that may ‘require special safeguards to reduce the risk of error’ was recently 
included in the list of high-alert medications [Clark, Simpson, Knox, and Garite, 2009: 
35.e1]. Clark et al. point out that recommendations on oxytocin administration currently 
used in practice are vague and that ‘in many instances, the apparent efficacy and safety 
of the various anecdotally derived means of administration (“the way we have always 
done it”) owe their success primarily to the resiliency of maternal-fetal biology rather 
than carefully considered scientific evidence’ [Clark et al., 2009: 35.e1]. Guidelines for 
oxytocin use in augmentation of labour are often based on and reflect various practices 
across institutions and countries.  
Recent evidence found oxytocin to be effective in shortening labour [Wei, Wo, Xu, Roy, 
Turcot and Fraser, 2007], but data from clinical trials did not support the belief that 
oxytocin reduces the rate of Caesarean sections [NICE National Collaborating Centre 
for Women’s and Children’s Health, 2007]. Although more evidence from clinical 
trials is currently available, systematic evidence for oxytocin use is still lacking [Bugg, 
Siddiqui, and Thornton, 2008]. Clinical trials are often small, exclude at-risk women, 
look at varied practices and report only selected maternal and neonatal outcomes. The 
problem also lies with the definition of ‘delay’ in the first and second stage of labour 
and, in practice, various criteria have been used [NICE National Collaborating Centre 
for Women’s and Children’s Health, 2007], as well as various oxytocin dosage regimens 
[Bugg et al., 2008; NICE National Collaborating Centre for Women’s and Children’s 
Health, 2007]. 
A summary of the evidence relating to augmentation of the first stage of labour 
suggests no differences in outcomes, other than shortening its duration [NICE [National 
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Collaborating Centre for Women’s and Children’s Health], 2007]. There was no evidence 
of abnormal foetal heart rate or of changes in the Caesarean section rate. Nevertheless, 
the NICE guidelines emphasise the need to monitor the foetal heart rate continuously 
when oxytocin is used for augmentation. The evidence comparing low-dose regimens 
(starting dose and an increment of up to 2mU/min) and high-dose regimens (starting 
dose and an increment of 4mU/min or more) shows that high-dose regimens result in 
shorter labours, lower Caesarean section rate and higher chance of vaginal delivery 
but more hyperstimulation of the uterine muscles. The data on neonatal outcomes were 
insufficient to draw any conclusions on neonatal morbidity and mortality. Current specific 
recommendations on oxytocin augmentation in the first stage include a consultation 
with the obstetrician about whether oxytocin should be considered. For multiparas, a 
full assessment, including an abdominal palpation and vaginal examination, is required. 
When oxytocin is used, the foetus needs to be continuously monitored; the time between 
dose increments should be at least 30 minutes and the dose should be increased until 
there are 4-5 contractions in 10 minutes. Women should also be advised to have a vaginal 
examination four hours after oxytocin is started. No evidence for oxytocin augmentation 
in the second stage of labour was identified. Moreover, since there is a risk of uterine 
rupture NICE guidelines do not recommend oxytocin use in this stage. 
The WHO recommendations, however, do not distinguish between augmentation in the 
first and second stages of labour [WHO, 2003a]. They suggest a starting dose of 2.5 
units in 500ml of dextrose (or normal saline). The dose should be increased until 3 
contractions lasting 40 seconds in 10 minutes are attained with maximum infusion rate 
of 60 drops per minute. If satisfactory contractions are not established, the concentration 
of oxytocin should be increased to 5 units in 500ml dextrose (or normal saline) with the 
same rate of infusion and increments as above. Women should be carefully observed 
throughout, and their pulse, blood pressure and contractions monitored; the foetal heart 
should be monitored every 30 minutes and the IV infusion should be stopped in the event 
of abnormal foetal heart rate or of uterine hyperstimulation. Apart from these differences, 
the guidelines provided by NICE and by WHO are alike in requiring oxytocin to be 
administered by IV infusion and the continuous monitoring of contractions and foetal 
heart rate.
Although the NICE guidelines summarise some high-quality evidence on oxytocin 
use in the first stage of labour, their conclusion emphasizes the importance of further 
research into the start dose and increments of oxytocin infusion. The data on neonatal 
outcomes were also insufficient. To provide clear recommendations for practice, the 
Cochrane Collaboration Group proposed two systematic reviews in 2008. These will 
aim to evaluate the available evidence on the effect of oxytocin administered because of 
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slow progress in the first stage of labour with respect to uterine hyperstimulation and its 
impact on changes in foetal heart rate, Caesarean section rate, and incidence of serious 
neonatal morbidity or perinatal death (e.g. birth asphyxia, neonatal encephalopathy, 
childhood disability), and maternal death or serious morbidity [Bugg et al., 2008]. 
A comparison will also be made between various dose regimes of oxytocin (i.e. 
starting doses and the increments in oxytocin infusion) [Mori, Ullman, Pledge, and 
Walkinshaw, 2008]. 
Although the clinical evidence is not always completely clear-cut, then, guidelines 
suggest that oxytocin should be administered intrapartum very cautiously and only 
under specific conditions because of the risks to the mother and her baby. The WHO 
practical guide from 1996, for instance, explicitly warned against the intramuscular 
administration of oxytocin because it is harmful for the foetus and increases the risk 
of uterine rupture. The guide also recommended that oxytocin augmentation should be 
restricted to labours supervised by obstetricians and to facilities that provide surgical 
services and (whenever possible) foetal surveillance by electronic monitoring [WHO, 
1996]. More recent WHO guidelines recommend either oxytocin IV infusion for labour 
augmentation, with the precautions outlined above [WHO, 2003a], or that oxytocin only 
be used for the prevention of PPH in the third stage of labour [WHO, 2003b]. 
Oxytocin in Active Management of Third Stage of Labour (AMTSL) 
A Cochrane systematic review has found active management of the third stage superior 
to expectant management in terms of blood loss, PPH, and shortened labour [Prendiville 
et al., 2000]. AMTSL is a package of interventions including early cord clamping and 
cutting, controlled cord traction to deliver the placenta, and the routine administration 
of a prophylactic uterotonic drug just before, with, or immediately after, the birth of the 
baby [Begley, Devane, Murphy, Gyte, McDonald, and McGuire, 2008].   
Clinical evidence suggests that oxytocin and syntometrine are the drugs of choice for 
preventing PPH. Meta-analyses of clinical trials showed that prophylactic oxytocin is 
effective in reducing both blood loss greater than 500ml (RR 0.50; 95 per cent CI 0.43 
to 0.59; 7 trials, more than 3000 women) and the need for therapeutic oxytocics (RR 
0.50; 95 per cent CI 0.39 to 0.64) [Cotter, Ness, & Tolosa, 2001]. When compared to 
oxytocin alone, syntometrine (a combination of oxytocin and ergometrine) is associated 
with a small but significant reduction in the risk of blood loss between 500 and 1000ml 
(RR 0.82; 95 per cent CI 0.71 to 0.95); side-side effects such as nausea, vomiting and 
elevated blood pressure are, however, more common due to ergometrine [Su, Chong, & 
Samuel, 2007]. Syntometrine should therefore not be administered to women with pre-
eclampsia or cardiac conditions. More data on the side-effects, optimal dose and route 
of administration of oxytocin are needed, however [Cotter et al., 2001]. In addition, the 
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question of optimal timing remains open: timing might affect the blood perfusion to 
the baby and the loss of maternal blood during the delivery, whilst uterotonics 
administered before the delivery of the baby may cause acute perinatal asphyxia 
[Begley et al., 2008]. The main recommendation is to administer the relevant drugs at 
the delivery of the anterior shoulder, but this might require additional staff to be present 
at the labour. Typically, it is more common to administer uterotonics intramuscularly 
or by IV infusion immediately after the birth of the baby. Oxytocics are, however, 
sometimes administered at the crowning of the head or even after the delivery of the 
placenta [Cotter et al., 2001]. 
On the other hand, oxytocin and ergot preparations are not stable in tropical climates: 
according to the product information for Syntocinon (a leading brand of synthetic 
oxytocin), it should be kept below 25°C and should not be frozen. In much of the Global 
South, especially in rural areas, health facilities are unlikely to have reliable electricity 
supplies or refrigeration facilities; heat-stable oxytocin is being developed, however. In 
addition, oxytocin and ergot preparations require syringe technologies and sterilisation 
equipment (although the “Uniject™” device might circumvent this). Thus, whilst 
oxytocin is very effective in preventing and controlling PPH, several recent clinical 
trials have studied the effectiveness of prostaglandins and particularly misoprostol, 
which is cheap, can be administered in pill form and is not heat labile. 
Other recent studies evaluated the impact of the various interventions entailed in 
AMTSL and showed some adverse neonatal outcomes, including an increased risk of 
acute perinatal asphyxia if uterotonics are administered before the baby’s delivery, and 
lower haematocrit levels and haemoglobin concentration up to six months after birth 
due to early cord clamping [McDonald and Middleton, 2008]. Little is known about the 
effects of particular components of AMTSL. Based on this, a new systematic review on 
‘active versus expectant management in the third stage of labour’ has been proposed 
[Begley et al., 2008]. Currently, only a protocol is available.  
AMTSL, then, is associated with some adverse effects (e.g. nausea, vomiting and 
hypertension when ergometrine was used as a part of the routine care) as well as having 
effects on the baby.  Nevertheless, organisations such as International Confederation of 
Midwives (ICM), International Federation of Gynaecology and Obstetrics (FIGO) and 
WHO have accepted the proposal in Prendiville et al [2000] that AMTSL should be 
applied routinely in maternity hospitals.  There are still some question-marks over the 
evidence about exactly how and when oxytocin should and should not be used. Some 
good quality clinical trials have been conducted but often they were small, based on 
different practices, and often reporting only selected maternal and neonatal outcomes. 
Therefore it is hard to compare them and to draw any conclusions and recommendations 
for best practice. Evidence on adverse neonatal outcomes is lacking. It is not known if 
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intrapartum interventions involving uterotonic drugs (such as oxytocin) enhance the 
risk of PPH [McDonald, Abbott, and Higgins, 2004], because intrapartum interventions 
have been studied separately from third stage interventions and little is known about 
how they impact on the need for further interventions postpartum. 
Oxytocin Availability in South Asia
With these considerations this in mind, we now shift our focus from the guidelines for 
oxytocin use to its availability and use in South Asia. During the Tracing Pharmaceuticals 
project, we interviewed medical representatives, in urban and rural settings alike. They 
said that they do not actively promote oxytocin—mainly because oxytocin sales are 
sufficiently buoyant for producing companies not to perceive any need for high-profile 
and energetic marketing strategies these days. Our interviews with wholesale stockists 
and retailers endorse this interpretation.6 
Table 2: Oxytocin Brands Available in India
Evatocin Neon Labs INJ Rs153.00 Rs15.30 
Foetocin TTK INJ Rs13.00 Rs13.00 
Gynotocin ACE (Svizera) INJ Rs14.87 Rs14.87 
Indox Ind Swift AMP Rs14.30 Rs14.30 
Oxybro Inj Cadila (Vibra) INJ Rs15.00 Rs15.00 
Oxystar Cadila (Genstar) INJ Rs17.00 Rs17.00 
Oxytocin Inj Prem Pharma INJ Rs13.50 Rs13.50 
Oxyton-5 Inga INJ Rs12.00 Rs12.00 
Pitocin Pfizer INJ Rs15.60 Rs15.60 
Syntocinon Novartis INJ Rs57.20 Rs11.44 
Syntocinon Novartis INJ Rs57.20 Rs11.44 
Source: CIMS India July-Oct 2006
Note: The dosage varies across products, with the majority containing 5iu/ml; Oxybro Inj contains 5iu/5ml, 
and Pitocin is available in the two dosages (5iu/ml and 5iu/5ml) at the same price. The dose is not known 
for Oxytocin Inj by Prem Pharma. Recommendations for the intramuscular injection of oxytocin in AMT-
SL are for 10iu and pharmaceutical companies might market oxytocin in such dosages in the future: this 
would provide room for confusion and quite possibly for even more dangerous use of intrapartum oxytocin 
such as we outline in this paper. 
We could not do a comprehensive study of oxytocin availability, but it can be readily 
obtained in disparate places, whether retail outlets near urban nursing homes and 
hospitals offering delivery facilities or small pharmacies in towns remote from large 
towns.  Our interviews and some spot checks on stocks in retail outlets, also indicated 
that oxytocin is well known, routinely kept in stock by wholesalers and retailers, and 
relatively cheap. Moreover, oxytocin can easily be purchased over-the-counter (as our 
research assistants did several times), despite being a prescription-only drug. Table 2 
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lists the brands of oxytocin marketed in India, their producers and prices: all are locally 
manufactured. 
Urban Obstetricians and Intrapartum Oxytocin Use
Active management of labour is high profile in obstetrics circles in contemporary 
India. For instance, Daftary and colleagues have produced “an indigenously developed 
protocol of labour management” [2003], whilst Shyam Desai, in his presidential address 
to the Federation of Obstetric and Gynaecological Societies of India (FOGSI), placed 
AML—including labour acceleration using oxytocics—at the heart of Safe Motherhood 
initiatives in India [Desai, 2005]. The use of oxytocics for augmentation is part of 
‘programmed labour’ discussed in several sources [e.g. Meena, Singhal, and Choudhary, 
2006; Yuel, Kaur, and Kaur, 2008]. 
Systematic evidence about intrapartum oxytocin usage in institutional deliveries in South 
Asia is hard to come by, however. Nevertheless, the urban obstetricians we interviewed 
during the Tracing Pharmaceuticals project strongly advocated AML. They took 
intrapartum oxytocin use for granted as routine, normal and appropriate in their repertoire 
of interventions, the drug of choice for augmenting labour. One described oxytocin as 
‘the spinal cord of our speciality’ (Interview, October 24, 2007 Bijnor, western Uttar 
Pradesh). Obstetricians, including those nearing retirement, said that they had been told 
during their medical training that oxytocin use intrapartum was appropriate and that such 
use had been widespread throughout their working lives. Several obstetricians provided 
off-the-cuff estimates of intrapartum oxytocin usage in their institutions—sometimes 
upwards of 70 per cent. Some of this apparently high usage might be because a high 
proportion of institutional deliveries are difficult labours. 
Nevertheless, oxytocin was also being used in pre-booked deliveries, which suggests a 
more routinised use, even when labours are progressing normally. A senior midwifery 
lecturer in Delhi described her arguments with staff at the Safdarjang Hospital—the 
government hospital where her trainee midwives received their practical training—when 
she wanted her students to experience ‘normal deliveries’. The hospital staff said they 
routinely administered oxytocin to all women in the labour wards because of pressure 
of numbers: women’s labours could not be protracted, because of bed shortages and 
a rapid through-put needed to be maintained (Interview, March 10, 2007 Delhi). Our 
own observational data (e.g. from two sessions of several hours each observing the 
labour room of a large teaching hospital in Kolkata), also suggest that oxytocin is used 
in a large proportion of institutional deliveries. We cannot adjudicate on whether such 
usage is over and above what might be classed as ‘medical need’, although the clinical 
guidelines suggest that oxytocin use should be exceptional rather than routine. 
Intrapartum oxytocin use, then, seems to be very common and highly valued in 
institutional deliveries in the region. Why this might be remains uncertain. Oxytocin use 
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may be a form of ‘crowd control’ to ensure that labour room beds are vacated quickly 
[cf. Van Hollen’s discussion of busy hospitals in Chennai city: Van Hollen, 2003a, b]. A 
government obstetrician suggested that intrapartum oxytocin use enables private doctors 
to regulate the time when women deliver: “Because everything is money-oriented 
exactly. They want to work in day, take rest in night.” (October 24, 2007 Bijnor). And 
in other research in Bijnor in 2002-4, lay people frequently (and cynically) suggested 
that the financial interests of non-government health care providers lead them to 
administer drugs (or conduct even more lucrative Caesarean sections).  Perhaps for 
several reasons, intrapartum oxytocin use seems to be normalised in institutional 
deliveries in the region. 
Moreover, the clinical guidelines for intrapartum oxytocin use are not necessarily being 
followed in institutional deliveries. Writing about Karnataka, Matthews et al. comment: 
“[m]ore than 90 per cent of all women, and more than 75 per cent of women with no 
complications, were given repeated injections or intravenous infusions of oxytocics to 
hasten labour. Women in private and mission hospitals were more likely to have a doctor 
present during the delivery, but even here most women received repeated injections of 
oxytocics to speed up labour” [Matthews, Ramakrishna, Mahendra, Kilaru, and Ganapathy, 
2005: 399; our emphasis]. An unpublished study in Jamshedpur also found that oxytocin 
use was routine in two hospitals (one government, one run by Tata), administered by 
different grades of staffs, sometimes IV but sometimes IM. In the government hospital, 
women received very little attention or monitoring, whereas monitoring was routine 
in the Tata hospital (Judith Sim, personal communication, 12 March 2009). During 
our observations in a Kolkata teaching hospital, women admitted to the labour ward 
were examined (to assess cervical dilatation and the baby’s presentation) and most were 
straightaway attached to IV saline drips containing oxytocin. Thereafter, checking of 
the drip, internal examinations, foetal heart monitoring, etc. were done infrequently and 
irregularly and there was no continuity of care. Labouring women were left to their own 
devices, often two to a bed, whilst staff spent much of their time congregated at a desk 
at one end of the ward. Discussing institutional deliveries and the incidence of neonatal 
encephalopathy in Kathmandu, Ellis comments that “the most striking potentially 
preventable risk factor for adverse outcome” was ‘induction of delivery’ using oxytocin 
infusion [Ellis, 1999: 167; see also Ellis, Manandhar, Manandhar, and Costello, 2000]. 
Similarly, although the evidence is sparse and unsystematic, intrapartum oxytocin use in 
hospital deliveries in low-income countries more generally seems to be associated with 
enhanced risks of stillbirth, neonatal resuscitation, neonatal deaths and uterine rupture 
[Lovold et al., 2008]. In brief, institutional deliveries are no guarantee either of quality 
of care or of safety. 
Intrapartum Use of Oxytocin in Rural Home Deliveries
Many studies in South Asia have shown that the bulk of health care, especially in rural 
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areas, is provided by private practitioners of various kinds—trained in various medical 
traditions or none—operating outwith the formal government health care system. Given 
the government sector’s lack of capacity, perhaps the private sector plugs an important 
gap in provision. In this case, though, oxytocin is being administered in circumstances 
that raise serious disquiet. Table 3 summarises how oxytocin is being used intrapartum 
in rural home deliveries in South Asia. In itself, of course, using oxytocin during 
home deliveries flouts the clinical guidelines because the recommended monitoring 
and emergency facilities are absent. Moreover, oxytocin is usually administered by 
intramuscular injection. A few studies indicate how frequently oxytocin is used, whilst 
others merely indicate that its use is commonplace and well-known. 
 
A study conducted in 12 Uttar Pradesh districts found that oxytocin was administered 
Table 3: Intrapartum Oxytocin Use: Practice in Rural Home Deliveries in South Asia
Exclusion of at-risk 
women
Regional variations in proportions of women covered by antenatal care in 
the formal health sector; most regimes do not include antenatal visits in late 
pregnancy, when many contra-indications would first become obvious. 
Parity Multiparous women often receive oxytocin, although its use is more common 
among primagravidae [Das et al., 2005; Sharan et al., 2005]. In the Bijnor study, 
62.3 per cent of primagravidae (n=53) received injections, compared with 45 per 
cent of women of higher parities (n=293) (unpublished data). 
Examination prior 
to administration of 
oxytocin
TBAs generally do external examinations but do not necessarily ascertain cervical 
dilatation before oxytocin administration; male practitioners generally perform 
no examinations: thus stage of labour, presentation and number of infant(s) are 
not necessarily ascertained. Several women in the Bijnor study reported footling 
breech or transverse presentations that were undiagnosed before oxytocin 
administration. 
Mode of administration Intramuscular injection (sometimes more than one); effective dose cannot be 
ascertained or regulated.
Monitoring the 
woman & foetus 
during oxytocin 
administration
TBAs may perform internal examinations but there is no monitoring equipment 
to detect foetal distress, assess frequency & strength of contractions or measure 
mother’s blood pressure etc. after oxytocin administration. 
Setting/availability of 
emergency facilities
No equipment for dealing with emergencies (resuscitation equipment, incubator 
etc. for small/weak babies, no operating facilities, anaesthesia, blood bank etc.); 
taking labouring women elsewhere presents problems of transport, money, time 
& distance.
Note: This table should be compared with Table 1, which outlines the clinical guidelines for intrapartum 
oxytocin use. The points listed in Table 3 are probably widely applicable in South Asia although few of the 
studies cited in the text explicitly mention them. This listing draws mainly on the research on childbearing 
in Bijnor district (western Uttar Pradesh) conducted by Patricia Jeffery and Roger Jeffery.
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in 48.2 per cent of home deliveries (n=2,992) across the state (ranging from 74.7 per 
cent in Muzaffarnagar to 16.7 per cent in Chitrakoot). Almost two-thirds of the women 
reporting injections had had more than one. Traditional birth attendants (TBAs) and 
auxiliary nurse-midwives (ANMs) were the primary decision-makers for using the 
injection (29.8 per cent and 29.6 per cent respectively) and informal private practitioners 
and ANMs were the primary injection service providers (48.2 per cent and 32.8 per cent 
respectively) [Das, Agarwal, Tripathi, and Parveen, 2005].  A study in rural Kanpur 
reported similar patterns of use, although absolute levels were lower (23 per cent, 
n=527), and there was a statistically significant relationship between injection use and 
the presence of a provider (trained or otherwise) [Sharan, Strobino, & Ahmed, 2005]. 
Research in two villages in Bijnor district, western Uttar Pradesh, indicates that between 
1983 and 1987, oxytocin was being administered in about 15 per cent of deliveries 
(n=237) by the government pharmacist as part of his (illegal) private practice [Jeffery, 
Jeffery, & Lyon, 1989:111-112]. In 1998–2002, oxytocin injections were administered 
by untrained private rural medical practitioners (male) in 48 per cent of deliveries 
(n=346) [Jeffery and Jeffery, 2008: 72]. In the early 2000s, these practitioners charged 
between Rs100 and Rs150 per injection, a considerable mark-up on the retail price of 
around Rs20 for a phial of 5iu of oxytocin, but not prohibitively expensive even for 
poor families. A Karnataka study reports that ‘injections to increase pains’ (probably 
oxytocics) were injected in 21 per cent of all home deliveries, including 51 per cent of 
those attended by government auxiliary nurse-midwives [Matthews et al., 2005:397; 
Ramakrishna, Ganapathy, Matthews, Mahendra, and Kilaru, 2008: 96; see also George, 
Iyer, and Sen, 2005 for a report on elsewhere in rural Karnataka]. Similarly, writing 
about rural Rajasthan, Iyengar notes that intramuscular oxytocin injections are ‘widely 
used’ intrapartum [Iyengar, Iyengar, Martines, Dashora, & Deora, 2008: S27], whilst 
Van Hollen describes its use by the local multi-purpose health worker as ‘almost routine’ 
during home deliveries in Tamilnadu [Van Hollen, 2003a, b]. Bang, Bang, Baitule, 
Reddy, and Dashmukh [2005] report that in rural Maharashtra oxytocin injections were 
administered by unqualified private practitioners)  in between 21.2 per cent and 23.1 
per cent of the cases they studied and that they raised the risk of birth asphyxia and 
stillbirth threefold. Similar usage was acknowledged in personal communications from 
colleagues in Bangladesh and Pakistan [Jeffery, Das, Dasgupta, and Jeffery, 2007].
During the Tracing Pharmaceuticals project, our interviews with rural practitioners 
(mostly untrained and working in a private capacity) also indicated that they are very 
familiar with oxytocin and that some routinely administered it by IM injection to augment 
labour. A few talked about the dangers of using oxytocin in home deliveries, but many 
administered oxytocin in circumstances comparable to those outlined above, generally 
at the behest of the labouring woman and/or her female attendants, or because the TBA 
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recommended its use. Oxytocin may also be used intrapartum in urban home deliveries: 
a study in a poor area of Delhi reported oxytocin use in 68.9 per cent of home deliveries, 
administered by private ‘doctors’ in 86.8 per cent of cases [Caleb, 1995]. Similar use has 
also been documented in Sudan and Guatemala [Lovold et al., 2008]. 
An additional feature of oxytocin is its cultural acceptability. In the local understanding 
of pregnancy, a woman’s body becomes increasingly ‘hot’ (in the humoral sense) until 
uterine contractions are sparked off. According to the Bijnor study, desi  [folk] methods 
of ‘heating’ a woman’s labour—‘heating’ drinks such as tea containing unrefined 
sugar, loosening her plaits, unlocking padlocks, etc.—were still common in the early 
1980s [Jeffery et al., 1989: 103ff.]. They had almost disappeared by the early 2000s 
and village women and their attendants regarded intrapartum oxytocin injections as the 
most effective method of speeding labour, especially in labours perceived to be lengthy 
and in which the contractions had ‘cooled’ (become infrequent or less intense).They 
were popular with women wanting their labour to end quickly and many women had 
several injections within a few hours. They called these injections dard barhāne kā tikkā 
[pain/contraction enhancing injection]. Other sources talk of garmī ri huī [Iyengar et 
al., 2008: S27] or garmī ki suī (heating injection), and other variants on the theme are 
widespread in the region. Further, as many sources suggest, hyperdermic needles are 
powerful icons of ‘modernity’. Based on her study in rural Sitapur (UP), Pinto argues 
that injections enable local practitioners to re-assert their quasi-institutional authority 
through association with modern biomedicine [Pinto, 2004, 2008]. In line with this, 
Das et al. found that intrapartum oxytocin use was greatest among women of higher 
socio-economic status and the relatively more educated, suggesting that it was used less 
because of need and more because of ability to pay and an association with ‘modernity’ 
[Das et al., 2005]. 
Many rural medical practitioners have no formal medical qualifications. Others have 
training in ayurveda, unani or homeopathy, but their practice usually includes, or is 
even dominated by, cosmopolitan remedies. Rural practitioners, however, have often 
had previous urban employment as compounders (pharmacists), ward boys, etc. in urban 
facilities. One explanation for how oxytocin use might have become widespread in the 
rural areas was proposed by several interviewees: that rural practitioners learn their 
trade primarily by observing clinical practices in urban facilities and adopt them in 
their rural practices. Interviews with rural practitioners also indicate that they maintain 
relationships with urban facilities, often accompanying labouring women whom they 
refer there (in the 2002-4 Bijnor study, villagers alleged that they take a commission 
for doing so). There are, then, many opportunities for them to observe oxytocin use in 
urban facilities. 
If urban usage fails to follow clinical guidelines, rural practitioners are unlikely to 
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appreciate the dangers of administering oxytocin injection in situations where they 
cannot adequately monitor the labour or provide emergency care if matters go awry. 
Indeed, even if urban practices do follow clinical guidelines, rural practitioners might not 
emulate them if they are unaware of the rationales behind them. In sum, the enthusiasm 
of obstetricians for using (and sometimes misusing) oxytocin intrapartum in urban 
nursing homes and hospitals probably leads directly and indirectly to its use and misuse 
in the rural areas—a series of unintended consequences that the urban practitioners we 
interviewed were generally unwilling to acknowledge.
Conclusions 
This paper has focused on intrapartum use of oxytocin in South Asia. More work is 
required to establish how commonplace intrapartum oxytocin use is in South Asia, 
whether in rural home deliveries or in urban institutions. We also do not know how much 
of that use departs from the clinical guidelines for its use and there are no data providing 
systematic information on the impact of such use on maternal mortality and morbidity, 
stillbirths and neonatal mortality and morbidity. The National Family Health Survey 
(NFHS)—the main source of national-level information about pregnancy, delivery and 
post-partum care in India—has collected nothing on intrapartum oxytocin use in its 
1992-1993, 1998-1999, and 2005-2006 rounds, for instance. 
Nevertheless, advocacy of AMTSL includes proposals to issue local-level health 
workers with oxytocin to avert and (if necessary) arrest post-partum haemorrhage. 
Policy documents, however, tend to present government programmes as if they are 
hermetically sealed from the wider world in which they are embedded. With respect to 
the use of oxytocin in AMTSL, they are silent about its significant life out with the realm 
of government policy and provision—indeed, a life that is also beyond its purview. 
The lack of concern about oxytocin misuse that has emanated from the professional 
and policy circles involved with issues of reproductive and child health is troubling. 
Our interviews with policy-makers and employees of NGOs in Delhi and Kathmandu, 
for instance, indicate that they are often aware of the kinds of oxytocin usage we have 
described, that they consider PPH a more significant issue than oxytocin misuse (despite 
the lack of evidence base) and that they are naïvely complacent about the prospects of 
retaining control over the oxytocin issued for AMTSL purposes. 
The policy recommendations have no robust mechanisms to prevent oxytocin designated 
for PPH prevention from being used intrapartum, whether in local-level facilities 
by government staff themselves or by seepage into the private sector. The health 
care market is huge, diverse and, of course, inflected with market incentives and the 
imperative to make money: its implications for Safe Motherhood initiatives must be 
addressed. To be realistic, women in South Asia (in many areas, the vast majority of 
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women) will continue to deliver their babies outside the government sector—and much 
greater attention must be paid to these ground realities if policy interventions are to 
have their hoped-for impact (and not to be undermined by their undesirable unintended 
consequences). Of course, intrapartum oxytocin (mis)use is not the only serious issue 
at stake for Safe Motherhood. But tracing how pharmaceuticals such as oxytocin 
are being used “on the ground” and understanding how they are embedded in wider 
social and economic contexts provides crucial support for our view that policy-makers 
urgently need to engage with the everyday realities of drug availability and use in the 
Global South. 
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Notes :
1 This paper emerged from the collaborative research project Tracing Pharmaceuticals in South Asia 
(2006-2009) that was jointly funded by the Economic and Social Research Council and the Department 
for International Development (RES-167-25-0110). The project team comprised: Soumita Basu, Gitanjali 
Priti Bhatia, Samita Bhattarai, Petra Brhlikova, Erin Court, Abhijit Das, Stefan Ecks, Ian Harper, Patricia 
Jeffery, Roger Jeffery, Sakshi Khurana, Rachel Manners, Allyson Pollock, Santhosh M.R., Nabin Rawal, 
Liz Richardson, and Madhusudhan Subedi. Martin Chautari (Kathmandu) and the Centre for Health and 
Social Justice (New Delhi) provided resources drawn upon in writing this paper. Neither ESRC nor DFID is 
responsible for views advanced here.
2 The ‘medicalisation’ of childbirth has not been uncritically accepted within professional circles, as well as 
beyond, but we cannot address this issue here. 
3  There are many possible variations of these three interventions. First, several uterotonic agents are available, 
with variations in timing, dose and route of administration (e.g. oxytocin can be administered as IV infusion 
or intramuscularly, syntometrine as an IM injection, and ergometrine IV or IM). Secondly, there are also 
possible variations in the timing of cord clamping and cutting and in the initiation of controlled cord traction. 
Variations in practice across health centres and countries mean that some women receive mixed management, 
a combination of expectant and active management that does not include all the components of either (Begley 
et al., 2008). For a discussion of the disparities in standards for AMTSL and in their implementation in practice 
of hospitals in developing countries, see Stanton, Armbruster, Knight, Ariawan, Gbangbade, Getachew 
et al. (2009). 
4 When misoprostol was used there was a higher risk of severe PPH (RR 1.32, 95 per cent CI 1.16 to 1.51; 
16 trials, 29042 women) and greater use of additional uterotonics but fewer blood transfusions (RR 0.81, 
95 per cent CI 0.64 to 1.02; 15 trials, 27858 women) than when injectable uterotonics (oxytocin IM or IV, 
ergometrine, ergometrine plus oxytocin) were used. Oral misoprostol (600mcg) was associated with higher 
rates of side-effects, such as nausea, vomiting, diarrhoea, shivering and pyrexia (greater than 38˚C) when 
compared with injectable uterotonics as well as placebo. Results from a small number of trials suggest that 
side-effects associated with misoprostol use are dose related and that rectal misoprostol resulted in less pyrexia 
and shivering than oral misoprostol (Gulmezoglu, Forna, Villar, & Hofmeyr, 2007). Although less effective 
in preventing PPH than oxytocin, misoprostol showed promising results when compared to placebo and for 
its easier administration was tested in home-deliveries in developing countries (Derman, Kodkany, Goudar, 
Geller, Naik, Bellad et al., 2006; Miller, Lester, & Hensleigh, 2004). More research on the optimal dose and 
mode of administration is needed if misoprostol is to be recommended for resource-poor settings. 
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5 Definitions of AMSTL differ slightly. FIGO-ICM prefer 10iu oxytocin administered by IM injection, or 
IV injection, drip or push after induction or augmentation within one minute of foetal delivery, with 0.2 
mg ergometrine administered in the same way as oxytocin or 600mcg misoprostol (oral tablet) or other 
prostaglandins as second line drugs. WHO prefer 10iu by IM injection oxytocin within one minute of the 
baby’s delivery, and if oxytocin is not available they recommend 0.2 mg IM ergometrine or prostaglandins; 
they also specify that a check is made before giving these medications that there are no additional baby(s): 
for more details, see http://www.who.int/reproductive-health/impac/Clinical_Principles/Normal_labour_
C57_C76.html#C73 per cent20Active per cent20management per cent20of per cent20the per cent20third per 
cent20stage
6 We have been unable trace data that provide overall information for South Asia on oxytocin sales over time, 
so we cannot comment on these assessments. 
7 We could not conduct a systematic study of drug transport and storage. This aspect merits further work for 
heat-labile drugs such as oxytocin, since turnover and seasonality may impact on drug efficacy.
8 Research on childbearing in Bijnor district (western Uttar Pradesh) was conducted by Patricia Jeffery and 
Roger Jeffery and funded by Social Science Research Council [now Economic and Social Research Council] 
in 1982-3 and 1985 and by Wellcome Trust in 2002-4). 
